25 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
thereof;
requirement by regulatory authorities of additional warnings on the label, such as a “black box” warning or contraindication;
requirement … are estimated on the date of issuance, and each subsequent balance sheet date, using the Black-Scholes valuation model using the appropriate risk-free interest
6-K
EX-99.1
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
share. The Company determined the fair value of the warrant on January 28, 2022 using the Black Scholes model by using a risk-free interest rate … the fair value of the warrants on March 1, 2022 using the Black Scholes model by using a risk-free interest rate of 1.72%, an expected term of 3 years
6-K/A
EX-99.1
OBSVF
ObsEva SA
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
. The warrant has an exercise price of USD 1.87 per share. The Company determined the fair value of the warrant on January 28, 2022 using the Black Scholes model … date of the registration statement which was March 1, 2022. The Company revalued the fair value of the warrants on March 1, 2022 using the Black Scholes
6-K
EX-99.1
OBSVF
ObsEva SA
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
. The warrant has an exercise price of USD 1.87 per share. The Company determined the fair value of the warrant on January 28, 2022 using the Black … revalued the fair value of the warrants on March 1, 2022 using the Black Scholes model by using a risk-free interest rate of 1.72%, an expected term of 3
6-K
EX-99.1
OBSVF
ObsEva SA
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
the fair value of the warrant on January 28, 2022 using the Black Scholes model by using a risk-free interest rate of 1.78%, an expected term of 3 … revalued the fair value of the warrants on March 1, 2022 using the Black Scholes model by using a risk-free interest rate of 1.72%, an expected term of 3
6-K
EX-99.2
43t323
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.1
3p6gi7t
31 Mar 21
Current report (foreign)
7:15am
6-K
EX-99.2
vp9zg0dhwsg3xj yc
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K/A
EX-99.1
4rzslzd m7w5bgx
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
EX-99.1
5cpmitcrtle7
13 Jan 21
Current report (foreign)
4:00pm
6-K
EX-99.1
dr8gs4stg9m1oxbd1qvx
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
EX-99.1
t0p63 zm6mf
14 Aug 20
Current report (foreign)
4:24pm
6-K
EX-99.1
4ono 039jmmewz5qx
7 Jul 20
Current report (foreign)
3:39pm
6-K
ny6aut988nd
15 Jan 20
Current report (foreign)
8:35pm
6-K
EX-99.2
qq8f1t41tavawbi7abw
10 Dec 19
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12:00am
6-K
6qa6yap rdq
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
6-K
EX-99.1
r6ybx6n9ua napoe
7 Aug 19
Current report (foreign)
7:21am